Blueprint Medicines Corporation

NasdaqGS:BPMC Stock Report

Market Cap: US$8.4b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Blueprint Medicines Management

Management criteria checks 2/4

Blueprint Medicines' CEO is Kate Haviland, appointed in Apr 2022, has a tenure of 3.25 years. total yearly compensation is $13.48M, comprised of 6.1% salary and 93.9% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $9.14M. The average tenure of the management team and the board of directors is 5 years and 10.2 years respectively.

Key information

Kate Haviland

Chief executive officer

US$13.5m

Total compensation

CEO salary percentage6.09%
CEO tenure3.3yrs
CEO ownership0.1%
Management average tenure5yrs
Board average tenure10.2yrs

Recent management updates

Recent updates

Seeking Alpha • Jun 18

Sanofi Buys Blueprint: Smart Move Suits All Parties, Warrants A Rating Upgrade

Summary Sanofi's deal to acquire Blueprint was announced on June 2nd ,for an initial amount of $9.1bn, or $129 per share. Sanoi will acquire Blueprint's approved drug for mastocytosis Aykavit, which earned $150m last quarter, and could reach $2bn in revenues by 2030. There are contingent value rights that may pay up to $6 per share based on a pipeline drug, BLU-808, achieving certain milestones. Sanofi had the money and the desire to do the deal, and the price paid will likely satisfy Bluerprint shareholders - up >600% since IPO. This is, therefore, a good deal for Sanofi, and Blueprint, and could kick off a bull run on stock, as Aykavit will be immediately revenue accretive. Read the full article on Seeking Alpha
User avatar
New Narrative • May 26

Expanding Patient Reach And Pipeline Development Will Unlock Potential

Strong AYVAKIT demand, expanded market reach, and improved therapy duration fuel revenue growth and enhance operating margin stability.
Seeking Alpha • Mar 29

Blueprint Medicines: Strong Business, Ambitious Targets, Expensive Stock

Summary Blueprint Medicines' primary revenue driver is Ayvakit, approved for various forms of Systemic Mastocytosis (SM) and showing strong growth, with 2024 revenues at $479m. The company projects Ayvakit to reach $2 billion in annual revenues by 2030, with significant growth potential as only 10% of the diagnosed SM market is penetrated. Blueprint is developing next-generation drugs like elenestinib and BLU-808, which could further enhance its SM franchise and diversify its revenue streams. Despite impressive growth and a strong cash position, I recommend a "hold" due to the stock's high valuation and the need for pipeline drugs to be further derisked. Read the full article on Seeking Alpha
Seeking Alpha • Sep 27

Blueprint Medicines: Growth For The Long Term Still Mostly Priced In

Summary Despite solid earnings beats, Blueprint Medicines is trading down ~16% since my last article. AYVAKIT/AYVAKYT revenues have doubled for four consecutive years, with 2024 guidance pegging net product revenue at $435-$450 million, a ~117% increase from 2023. CEO Haviland highlights AYVAKIT's multibillion-dollar potential, driven by its unique value proposition and strong adoption among physicians, patients, and payers. Blueprint's revised revenue guidance is based on strong first-half 2024 performance and growing experience with factors driving its business, particularly in systemic mastocytosis treatment. Read the full article on Seeking Alpha
Seeking Alpha • Jul 16

Blueprint Medicines: Overdue For A Breather

Summary Today, we take a look at Blueprint Medicines Corporation, a company focused on developing precision therapies for cancers and blood disorders. Blueprint's Q1 results were spectacular, and the company has a solid balance sheet, but the stock is up more than 150% from its lows in late October. Can the shares rally further, or are they overdue for a breather?  An analysis follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • May 04

Blueprint Medicines: Rampant Growth Mostly Priced In

Summary Blueprint Medicines generates growing revenues from its FDA-approved product AYVAKIT/AYVAKYT. AYVAKIT has been approved for multiple indications, including gastrointestinal stromal tumor and systemic mastocytosis. Blueprint reported strong Q1 2024 earnings, achieving $92.5 million in AYVAKIT net product revenues and raising guidance for full-year revenues. Read the full article on Seeking Alpha
Seeking Alpha • Feb 20

Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)

Summary Blueprint Medicines' Ayvakit shows strong performance in the ISM market, with revenue projections increased to $2 billion. Q4 '23 earnings highlight significant growth, with Ayvakit driving revenues up and a strong cash position despite a high burn rate. Market sentiment is robust, supported by strong analyst projections, institutional interest, and stock momentum. I am upgrading my rating to a "strong buy," considering Ayvakit's market potential, financial health, and Blueprint's strategic positioning despite biotech investment risks. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Kate Haviland's remuneration changed compared to Blueprint Medicines's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$156m

Dec 31 2024US$13mUS$821k

-US$67m

Sep 30 2024n/an/a

-US$128m

Jun 30 2024n/an/a

-US$205m

Mar 31 2024n/an/a

-US$288m

Dec 31 2023US$6mUS$782k

-US$507m

Sep 30 2023n/an/a

-US$555m

Jun 30 2023n/an/a

-US$554m

Mar 31 2023n/an/a

-US$581m

Dec 31 2022US$6mUS$701k

-US$558m

Sep 30 2022n/an/a

-US$718m

Jun 30 2022n/an/a

-US$702m

Mar 31 2022n/an/a

-US$650m

Dec 31 2021US$4mUS$501k

-US$644m

Sep 30 2021n/an/a

-US$411m

Jun 30 2021n/an/a

US$340m

Mar 31 2021n/an/a

US$325m

Dec 31 2020US$2mUS$461k

US$314m

Sep 30 2020n/an/a

US$333m

Jun 30 2020n/an/a

-US$395m

Mar 31 2020n/an/a

-US$371m

Dec 31 2019US$3mUS$432k

-US$348m

Sep 30 2019n/an/a

-US$362m

Jun 30 2019n/an/a

-US$340m

Mar 31 2019n/an/a

-US$267m

Dec 31 2018US$3mUS$393k

-US$237m

Compensation vs Market: Kate's total compensation ($USD13.48M) is above average for companies of similar size in the US market ($USD8.78M).

Compensation vs Earnings: Kate's compensation has increased whilst the company is unprofitable.

CEO

Kate Haviland (49 yo)

3.3yrs
Tenure
US$13,477,004
Compensation

Ms. Kathryn Haviland, also known as Kate, M.B.A, is Independent Director of Bicara Therapeutic, Inc. from September 2023. She has been a Director of Fulcrum Therapeutics, Inc. since June 27, 2018. She serv...

Leadership Team

NamePositionTenureCompensationOwnership
Kathryn Haviland
President3.3yrsUS$13.48m0.11%
$ 9.1m
Alexis Borisy
Co-Founder & Directorno dataUS$549.69k0.11%
$ 9.6m
Michael Landsittel
Chief Financial Officer9.4yrsUS$4.19m0.067%
$ 5.6m
Christina Rossi
Chief Operating Officer3.3yrsUS$6.54m0.032%
$ 2.7m
Percy Carter
Chief Scientific Officer4.2yrsUS$5.13m0.082%
$ 6.9m
Fouad Namouni
President of Research & Development4.8yrsUS$5.50m0.049%
$ 4.1m
Ariel Hurley
Senior Vice President of Finance and Principal Accounting Officerno datano data0.026%
$ 2.2m
Jenna Cohen
Senior Director & Head of Investor Relationsno datano datano data
Tracey McCain
Executive VP8.8yrsUS$2.34m0.057%
$ 4.8m
Debra Durso-Bumpus
Chief People Officer5.4yrsno data0.035%
$ 3.0m
Julian Baker
Senior Vice President of Corporate Affairsno datano datano data
Becker Hewes
Chief Medical Officer5.2yrsno data0.047%
$ 3.9m
5.0yrs
Average Tenure
55yo
Average Age

Experienced Management: BPMC's management team is seasoned and experienced (5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kathryn Haviland
President3.3yrsUS$13.48m0.11%
$ 9.1m
Alexis Borisy
Co-Founder & Director14.3yrsUS$549.69k0.11%
$ 9.6m
George Demetri
Chair of Scientific Advisory Board13.2yrsUS$333.38kno data
Lynn Seely
Lead Independent Director9.3yrsUS$606.19k0.020%
$ 1.7m
Charles Sawyers
Member of Scientific Advisory Boardno datano datano data
Brian Druker
Member of Scientific Advisory Boardno datano datano data
Nicholas Lydon
Member of Scientific Advisory Board & Independent Director14.3yrsUS$569.69k0.086%
$ 7.2m
Lonnel Coats
Independent Director9.4yrsUS$572.59k0.0035%
$ 289.6k
William Hahn
Member of Scientific Advisory Boardno datano datano data
Scott Lowe
Member of Scientific Advisory Boardno datano datano data
Daniella Beckman
Independent Director3.6yrsUS$574.69k0.017%
$ 1.4m
Jeffrey Albers
Chairman of the Board of Director11yrsUS$586.19k0.22%
$ 18.7m
10.2yrs
Average Tenure
63yo
Average Age

Experienced Board: BPMC's board of directors are seasoned and experienced ( 10.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/17 19:39
End of Day Share Price 2025/07/17 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Blueprint Medicines Corporation is covered by 10 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
George FarmerBMO Capital Markets Equity Research
Dane LeoneBTIG
Arlinda LeeCanaccord Genuity